Review article: Intragastric and oesophageal pH monitoring in patients with gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue SUPPL. 1, 2006, Pages 3-11

  Katz, P O ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; STOMACH SECRETION INHIBITOR;

BARRETT ESOPHAGUS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ESOPHAGUS PH; FOOD DRUG INTERACTION; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LOW DRUG DOSE; PALLIATIVE THERAPY; PATIENT MONITORING; PH MEASUREMENT; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; SINGLE DRUG DOSE; STOMACH FUNDOPLICATION; STOMACH PH; SYMPTOMATOLOGY; TITRIMETRY; TREATMENT FAILURE;

ANTI-ULCER AGENTS; ESOPHAGITIS, PEPTIC; ESOPHAGUS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MONITORING, PHYSIOLOGIC; MUCOUS MEMBRANE; PROTON PUMPS; SEVERITY OF ILLNESS INDEX; STOMACH;

EID: 33645514432     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02801.x     Document Type: Review

References (35)

1. DeVault KR Castell DO American College of Gastroenterology Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease Am J Gastroenterol 2005 100 190 200
2. Frazzoni M De Micheli E Savarino V Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease Aliment Pharmacol Ther 2003 18 1091 8
3. Campos GM Peters JH DeMeester TR Oberg S Crookes PF Mason RJ The pattern of esophageal acid exposure in gastroesophageal reflux disease influences the severity of the disease Arch Surg 1999 134 882 7
4. Baldi F Ferrarini F Longanesi A Ragazzini M Barbara L Acid gastroesophageal reflux and symptom occurrence. Analysis of some factors influencing their association Dig Dis Sci 1989 34 1890 3
5. Ward BW Wu WC Richter JE Lui KW Castell DO Ambulatory 24-h esophageal pH monitoring. Technology searching for a clinical application J Clin Gastroenterol 1986 8 Suppl. 1 59 67
6. Wiener GJ Richter JE Copper JB Wu WC Castell DO The symptom index: a clinically important parameter of ambulatory 24-h esophageal pH monitoring Am J Gastroenterol 1988 83 358 61
7. Singh S Richter JE Bradley LA Haile JM The symptom index. Differential usefulness in suspected acid-related complaints of heartburn and chest pain Dig Dis Sci 1993 38 1402 8
8. Dekel R Martinez-Hawthorne SD Guillen RJ Fass R Evaluation of symptom index in identifying gastroesophageal reflux disease-related noncardiac chest pain J Clin Gastroenterol 2004 38 24 9
9. Breumelhof R Smout AJ The symptom sensitivity index: a valuable additional parameter in 24-h esophageal pH recording Am J Gastroenterol 1991 86 160 4
10. Weusten BL Roelofs JM Akkermans LM Van Berge-Henegouwen GP Smout AJ The symptom-association probability: an improved method for symptom analysis of 24-h esophageal pH data Gastroenterology 1994 107 1741 5
11. Colas-Atger E Bonaz B Papillon E et al Relationship between acid reflux episodes and gastroesophageal reflux symptoms is very inconstant Dig Dis Sci 2002 47 645 51
12. Taghavi SA Ghasedi M Saberi-Firoozi M et al. Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole Gut 2005 54 1067 71
13. Vela MF Camacho-Lobato L Srinivasan R Tutuian R Katz PO Castell DO Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole Gastroenterology 2001 120 1599 606
14. Charbel S Khandwala F Vaezi MF The role of esophageal pH monitoring in symptomatic patients on PPI therapy Am J Gastroenterol 2005 100 283 9
15. Milkes D Gerson LB Triadafilopoulos G Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD) Am J Gastroenterol 2004 99 991 6
16. Katz PO Lessons learned from intragastric pH monitoring J Clin Gastroenterol 2001 33 107 13
17. Pleskow D Rothstein R Lo S et al Endoscopic full-thickness plication for the treatment of GERD: 12-month follow-up for the North American open-label trial Gastrointest Endosc 2005 61 643 9
18. Eubanks TR Omelanczuk P Richards C Pohl D Pellegrini CA Outcomes of laparoscopic antireflux procedures Am J Surg 2000 179 391 5
19. Maqbool S Bhat YM Khandwala F et al. Barrett's esophagus: How much acid suppression is enough? Predictors of response to high dose proton pump inhibitors Am J Gastroenterol 2004 99 S10
20. Sharma P Reker D Weston A et al. Normalization of intra-esophageal pH in patients with Barrett's esophagus (BE) on rabeprazole and relationship of pH to Barrett's length and hiatal hernia Am J Gastroenterol 2002 97 S37
21. Katzka DA Castell DO Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus Am J Gastroenterol 1994 89 989 91
22. Ouatu-Lascar R Triadafilopoulos G Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus Am J Gastroenterol 1998 93 711 6
23. Fass R Sampliner RE Malagon IB et al Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor Aliment Pharmacol Ther 2000 14 597 602
24. Bell NJ Burget D Howden CW Wilkinson J Hunt RH Appropriate acid suppression for the management of gastro-oesophageal reflux disease Digestion 1992 51 Suppl. 1 59 67
25. Tutuian R Katz P Castell D A PPI is a PPI is a PPI: lessons learned from prolonged intragastric pH monitoring Gastroenterology 2000 118 Suppl. 2, pt 1 A17 Abstract 332
26. Miner Jr P. Katz PO Chen Y Sostek M Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study Am J Gastroenterol 2003 98 2616 20
27. Pantoflickova D Dorta G Ravic M Jornod P Blum AL Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors Aliment Pharmacol Ther 2003 17 1507 14
28. Richter JE Kahrilas PJ Johanson J et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial Am J Gastroenterol 2001 96 656 65
29. Castell DO Kahrilas PJ Richter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis Am J Gastroenterol 2002 97 575 83
30. Robinson M Fitzgerald S Hegedus R Murthy A Jokubaitis L FAST Trial Investigators Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis Aliment Pharmacol Ther 2002 16 445 54
31. Katz PO Hatlebakk JG Castell DO Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole Aliment Pharmacol Ther 2000 14 709 14
32. Hatlebakk JG Katz PO Camacho-Lobato L Castell DO Proton pump inhibitors: better acid suppression when taken before a meal than without a meal Aliment Pharmacol Ther 2000 14 1267 72
33. Hatlebakk JG Katz PO Kuo B Castell DO Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily Aliment Pharmacol Ther 1998 12 1235 40
34. Pehlivanov ND Olyaee M Sarosiek I McCallum RW Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study Aliment Pharmacol Ther 2003 18 883 90
35. Leite LP Johnston BT Just RJ Castell DO Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy Am J Gastroenterol 1996 91 1527 31